Advertisement

Drugs

, Volume 62, Issue 1, pp 1–11 | Cite as

The Value of Adjuvant Treatment in Young Women with Breast Cancer

  • Sally Clive
  • J. Michael Dixon
Current Opinion

Abstract

The postoperative management of breast cancer is an ever-changing field. Young patients, in particular, have attracted recent interest as it has become apparent that age alone is a poor prognostic indicator for breast cancer. Adjuvant therapies indisputably delay breast cancer recurrence and save lives, and should be considered for all young patients.

Chemotherapy is increasingly being considered appropriate for all women under the age of 35 years, regardless of other risk factors, but poses the particularly difficult problem of infertility for these young women. As the additional benefits of anthracyclines and taxanes in the adjuvant setting become clear, chemotherapy regimens are also becoming increasingly intensive and the risk of myocardial damage and leukaemia should not be ignored. The benefits of chemotherapy need to be weighed against the possible dangers, and therapy should be individualised according to cancer pathology and patient circumstance.

Tamoxifen should be given for 5 years to all women whose cancer is estrogen receptor positive, regardless of whether the patient has received chemotherapy. If chemotherapy is not given, the addition of luteinising hormone-releasing hormone (LHRH) agonists to tamoxifen in patients with estrogen receptor positive breast cancers appears to be beneficial. The addition of LHRH agonists to chemotherapy and tamoxifen is currently being evaluated in randomised trials.

Radiotherapy should be given after breast conservation surgery, and should include the axilla if nodes are involved and the axilla has not been surgically cleared. Chest wall radiotherapy should be considered following mastectomy in young women considered at high risk of local recurrence, but the long-term morbidity and mortality of local radiation therapy, which is increased in young women, needs to be considered.

Keywords

Breast Cancer Tamoxifen Adjuvant Setting Premature Ovarian Failure Dexrazoxane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hill AD, Doyle JM, McDermott EW, et al. Hereditary breast cancer. Br J Surg 1997; 84(10): 1334–9PubMedCrossRefGoogle Scholar
  2. 2.
    Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. JNatl Cancer Inst 1999; 91(11): 943–9CrossRefGoogle Scholar
  3. 3.
    Malone KE, Daling JR, Neal C, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000; 88(6): 1393–402PubMedCrossRefGoogle Scholar
  4. 4.
    John EM, Kelsey J. Radiation and other environmental exposures and breast cancer. Epidemiol Rev 1993; 15: 157–62PubMedGoogle Scholar
  5. 5.
    Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18(3): 498–509PubMedGoogle Scholar
  6. 6.
    van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18(3): 487–97PubMedGoogle Scholar
  7. 7.
    Yildirim E, Dalgic T, Berberoglu U. Prognostic significance of young age in breast cancer. J Surg Oncol 2000; 74(4): 267–72PubMedCrossRefGoogle Scholar
  8. 8.
    Kroman N, Jensen M-J, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000; 320: 474–9PubMedCrossRefGoogle Scholar
  9. 9.
    de la Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993; 341(8852): 1039–43PubMedCrossRefGoogle Scholar
  10. 10.
    Nixon AJ, Neuberg D, Hayes DF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994; 12: 888–94PubMedGoogle Scholar
  11. 11.
    Bertheau P, Steinberg SM, Merino MJ. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 1998; 29: 323–9PubMedCrossRefGoogle Scholar
  12. 12.
    Walker RA, Lees E, Webb MB, et al. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996; 74(11): 1796–800PubMedCrossRefGoogle Scholar
  13. 13.
    Agrup M, Stal O, Olsen K, et al. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 2000; 63(1): 23–9PubMedCrossRefGoogle Scholar
  14. 14.
    Gajdos C, Tartter PI, Bleiweiss IJ, et al. Stage 0 to stage III breast cancer in young women. J Am Coll Surg 2000; 190(5): 523–9PubMedCrossRefGoogle Scholar
  15. 15.
    Kollias J, Elsten CW, Ellis IO, et al. Early-onset breast cancer: histopathological and prognostic considerations. Br J Cancer 1997; 75(9): 1318–23PubMedCrossRefGoogle Scholar
  16. 16.
    Fowble BL, Schultz DJ, Overmoyer B, et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994; 30(1): 23–33PubMedCrossRefGoogle Scholar
  17. 17.
    Winchester DP, Osteen RT, Menck HR. The national cancer database report on breast carcinoma characteristics and outcome in relation to age. Cancer 1996; 78(8): 1838–43PubMedCrossRefGoogle Scholar
  18. 18.
    Chung M, Chang HR, Bland KI, et al. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996; 77(1): 97–103PubMedCrossRefGoogle Scholar
  19. 19.
    Miller RW, Ellis IO, Sainsbury JRC. Prognostic factors. In: Dixon JM, editor. ABC of breast diseases. 2nd ed. London: BMJ Publishing Group, 2000: 72Google Scholar
  20. 20.
    Dixon JM, Baum M. Clinical trials of management of breast cancer. In: Dixon JM, editor. ABC of breast diseases. 2nd ed. London: BMJ Publishing Group, 2000: 82Google Scholar
  21. 21.
    Group EBCT. Polychemotherapy for early breast cancer: overview of the randomised trials. Lancet 1998; 352: 930–42CrossRefGoogle Scholar
  22. 22.
    Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90: 1601–8PubMedCrossRefGoogle Scholar
  23. 23.
    Kroman N, Jensen M-J, Wohlfahrt J, et al. Should all younger patients with breast cancer be offered adjuvant cytotoxic chemotherapy? [in Dutch]. Ugeskr Laeger 2000; 162(22): 3184–8PubMedGoogle Scholar
  24. 24.
    Kollias J, Murphy CA, Eisten CW, et al. The prognosis of small primary breast cancers. Eur J Cancer 1999; 35(6): 908–12PubMedCrossRefGoogle Scholar
  25. 25.
    Group EBCT. Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 1998; 351: 1451–67CrossRefGoogle Scholar
  26. 26.
    Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330(18): 1260–6PubMedCrossRefGoogle Scholar
  27. 27.
    Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90(18): 1361–70PubMedCrossRefGoogle Scholar
  28. 28.
    Coombes RC, Bliss JM, Wils J, et al. Adjuvant cyclophosph-amide, methotrexate and flourouracil versus flourouracil, epirubicin, cyclophosphamide chemotherapy in premeno-pausal women with axillary node positive operable breast cancer: results of a randomised trial. J Clin Oncol 1996; 14(1): 35–45PubMedGoogle Scholar
  29. 29.
    Levine MN, Bramwell VH, Pritchard KI, et al. Randomised trial of intensive cyclophosphamide, epirubicin and 5 flourouracil chemotherapy compared with cyclophosphamide, methotrexate and flourouracil in premenopausal women with node positive breast cancer. J Clin Oncol 1998; 16(8): 2651–8PubMedGoogle Scholar
  30. 30.
    Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than 3 positive nodes: 10 year results. JAMA 1995; 273(7): 542–7PubMedCrossRefGoogle Scholar
  31. 31.
    Henderson IC. Improved disease-free survival and overall survival from the addition of sequential paclitaxel in the adj uvant chemotherapy of patients with node-positive primary breast cancer. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology (ASCO); 1998 May 16–19: Los Angeles (CA), 390AGoogle Scholar
  32. 32.
    Thomas E, Buzdar A, Theriault R, et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trial [abstract]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO); 2000 May 20–23: New Orleans (LA), 19: 74Google Scholar
  33. 33.
    Crown J, O’Leary M. The taxanes: an update. Lancet 2000; 355(9210): 1176–8PubMedCrossRefGoogle Scholar
  34. 34.
    Abrams JS. North American adjuvant breast cancer trials. Recent Results Cancer Res 1998; 152: 417–28PubMedCrossRefGoogle Scholar
  35. 35.
    Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian breast group 9401 study. Lancet 2000; 356(9239): 1384–91Google Scholar
  36. 36.
    Peters W, Rosner G, Vredenburgh J, et al. A prospective randomised comparison of 2 doses of combination alkylating agents (AA) as consolidation after CAF in high risk primary breast cancer involving 10 or more axillary lymph nodes: preliminary results of CALGB9082/SWOG91104/NCICMA-13 [abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999 May 15–18: Atlanta (GA), 18: 1Google Scholar
  37. 37.
    Norton L, Slamon D, Leyland-Jones B, et al. Overall survival (OS) advantage to simultaneous chemotherapy plus humanised anti HER2 monoclonal antibody Herceptin in HER2: overexpressing metastatic breast cancer [abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999 May 15–18: Atlanta (GA), 18: 127Google Scholar
  38. 38.
    McNeil C. Herceptin in the adjuvant setting: phase III trials begin. J Natl Cancer Inst 2000; 92(9): 683–4PubMedCrossRefGoogle Scholar
  39. 39.
    Baselga J. Current and planned clinical trials with trastuzumab. Semin Oncol 2000; 27 (5 Suppl. 9): 27–32PubMedGoogle Scholar
  40. 40.
    Tollenaar RA, Liefers GJ, Repelaer van Driel OJ, et al. Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer. Eur J Cancer 1994; 30A(10): 1448–53PubMedCrossRefGoogle Scholar
  41. 41.
    Dow KH, Lafferty P. Quality of life, survivorship, and psychosocial adjustment of young women with breast cancer after breast-conserving surgery and radiation therapy. Oncol Nurs Forum 2000; 27(10): 1555–64PubMedGoogle Scholar
  42. 42.
    Broeckel JA, Jacobsen PB, Balducci L, et al. Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2000; 62(2): 141–50PubMedCrossRefGoogle Scholar
  43. 43.
    Joly F, Espie M, Marty M, et al. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer 2000; 83(5): 577–82PubMedCrossRefGoogle Scholar
  44. 44.
    Sparano JA, Hu P, Rao RM, et al. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an eastern cooperative oncology group study. J Clin Oncol 1999; 17(12): 3823–34Google Scholar
  45. 45.
    Gennari A, Salvadori B, Donati S, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 1999; 17(11): 3596–602PubMedGoogle Scholar
  46. 46.
    Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17(10): 3333–55PubMedGoogle Scholar
  47. 47.
    Valagussa P, Moliterni A, Tereziani M, et al. Second malignancies following CMF-based adjuvant chemotherapy in resect-able breast cancer. Ann Oncol 1994; 5(9): 803–8PubMedGoogle Scholar
  48. 48.
    Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and flurouracil in positve-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the national surgical adjuvant breast and bowel project B-15. J Clin Oncol 1990; 8(9): 1483–96PubMedGoogle Scholar
  49. 49.
    Collichio FA, Agnello R, Staltzer J. Pregnancy after breast cancer: from psychosocial issues through conception. Oncology (Huntingt) 1998; 12(5): 759–65,769,773-5Google Scholar
  50. 50.
    Reichman BS, Green KB. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects. J Natl Cancer Inst Monogr 1994; 16: 125–9PubMedGoogle Scholar
  51. 51.
    Myers SE, Schilsky RL. Prospects for fertility after cancer chemotherapy. Semin Oncol 1992; 19(5): 597–604PubMedGoogle Scholar
  52. 52.
    Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339(6): 357–63PubMedCrossRefGoogle Scholar
  53. 53.
    Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25(2): 137–45PubMedCrossRefGoogle Scholar
  54. 54.
    Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998; 45(6): 608–12PubMedCrossRefGoogle Scholar
  55. 55.
    Bertzen SM, Skocylas JZ, Overgaard M, et al. Radiotherapy related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996; 88(13): 918–20CrossRefGoogle Scholar
  56. 56.
    Bianco AR, De Laurentiis M, Carlomagno C, et al. Her2 over-expression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): complete data at 20 yr of the Naples GUN randomized trial [abstract]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO); 2000 May 20–23: New Orleans (LA), 19: 75Google Scholar
  57. 57.
    Nordenskjold B, Carstensen J, Rutqvist L, et al. Prolonged follow-up of the Swedish randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer and relationships to hormone receptor and ErbB2 levels [abstract]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO); 2000 May 20–23: New Orleans (LA), 19: 72Google Scholar
  58. 58.
    De Laurentiis M, Arpino G, Massarelli E, et al. A metanalysis of the interaction between Her2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC) [abstract]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO); 2000 May 20–23: New Orleans (LA), 19: 78Google Scholar
  59. 59.
    Fisher B, Dingham J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and ER positive tumours. J Natl Cancer Inst 1996; 88: 1529–42PubMedCrossRefGoogle Scholar
  60. 60.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomised trial. J Natl Cancer Inst 2001; 93(9): 684–90PubMedCrossRefGoogle Scholar
  61. 61.
    Tormey D, Gray R, Falkson H. Post chemotherapy adjuvant tamoxifen beyond 5 years in patients with lymph node positive breast cancer. J Natl Cancer Inst 1996; 88: 1828–33PubMedCrossRefGoogle Scholar
  62. 62.
    Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br J Cancer 1996; 74: 297–9PubMedCrossRefGoogle Scholar
  63. 63.
    Baum M. Tamoxifen: the treatment of choice. Why look for alternatives? Br J Cancer 1998; 78 Suppl. 4: 1–4Google Scholar
  64. 64.
    Buzdar AU, Hortobagyi G. Update of endocrine therapy for breast carcinoma. Clin Cancer Res 1998; 4: 527–34PubMedGoogle Scholar
  65. 65.
    Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. J Natl Cancer Inst 1994; 86(7): 527–37PubMedCrossRefGoogle Scholar
  66. 66.
    Dixon JM, Baum M. Clinical trials of management of breast cancer. In: Dixon JM, editor. ABC of breast diseases, 2nd ed. London: BMJ Publishing Group, 2000: 81Google Scholar
  67. 67.
    Saarto T, Blomguvist C, Ehnholm C, et al. Anti-atherogenic effect of adjuvant anti-oestrogens. J Clin Oncol 1996; 14(2): 429–33PubMedGoogle Scholar
  68. 68.
    Locker GY. Hormonal therapy of breast cancer. Cancer Treat Rev 1998; 24: 221–46PubMedCrossRefGoogle Scholar
  69. 69.
    Group EBCTC. Ovarian ablation in early breast cancer: overview of randomised trials. Lancet 1996; 348: 1189–96CrossRefGoogle Scholar
  70. 70.
    Group EBCTC. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1–15, 71–85Google Scholar
  71. 71.
    Roche HH, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients (pts) with positive hormone-receptor (HR+) and 1–3 node-positive (N+) tumor: results of the FASG 06 trial [abstract]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO); 2000 May 20–23: New Orleans (LA), 19: 72Google Scholar
  72. 72.
    Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosph-amide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian breast cancer adjuvant study group 02 randomized trial. J Clin Oncol 2000; 18(14): 2718–27PubMedGoogle Scholar
  73. 73.
    Pritchard KI. Current and future directions in medical therapy for breast carcinoma. Cancer 2000; 88 Suppl 12: 3065–72PubMedCrossRefGoogle Scholar
  74. 74.
    Jakesz R, Gnant M, Hausmaninger H, et al. Combination goserelin and tamoxifen is more effective than CMF in premenopausal patients with hormone responsive tumors in a multicenter trial of the Austrian breast cancer study group [abstract]. Breast Cancer Res Treat 1999; 57(1): 25Google Scholar
  75. 75.
    Davidson NE, O’Neill A, Vukov A, et al. Effect of chemo-hormonal therapy in premenopausal node positive receptor positive breast cancer: an eastern cooperative oncology group phase III intergroup trial (E5188, INT-0101). Breast 1999; 8: 232–3CrossRefGoogle Scholar
  76. 76.
    Baum M, Rutgers EE. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomized trial by the cancer research campaign (CRC) breast cancer trials group, the Stockholm breast cancer study group, the south-east Sweden breast cancer group and the gruppa interdisciplinara valurazione interventl in oncologia (GIVIO) [abstract]. The Breast 1999; 8: 233Google Scholar
  77. 77.
    Bartelink H. Post-mastectomy radiotherapy: recommended standards. Ann Oncol 2000; 11 Suppl. 3: 7–11PubMedGoogle Scholar
  78. 78.
    Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer: a meta-analysis. J Clin Oncol 2000; 18: 1220–9PubMedGoogle Scholar
  79. 79.
    Van de Steene J, Soete G, Storme G. Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. Radiother Oncol 2000; 55(3): 263–72PubMedCrossRefGoogle Scholar
  80. 80.
    Group EBCTC. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: and overview of the randomised trials. Lancet 2000; 355(9217): 1757–70CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Department of OncologyWestern General HospitalEdinburghUK
  2. 2.Western General HospitalUniversity of Edinburgh and Edinburgh Breast UnitEdinburghUK

Personalised recommendations